Further studies are required to establish the E protein as a ligand for direct binding to TLR2. In contrast to the pathogenic role of TLR2 in inducing excess inflammation, intranasal administration of INNA-051, a TLR2/TLR6 agonist, reduces the level of viral RNA in nose and throat swabs from SARS-CoV-2–infected ferrets [21], suggesting that stimulation of TLR2 in specific tissues may be beneficial in preventing the development of COVID-19 by reducing SARS-CoV-2 transmission. This evidence concerns the gene TLR2 and COVID-19.